Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (trading symbol: EKSO) on May 22, 2019. The registrant is an emerging growth company incorporated in Nevada. The report details the entry into a material definitive agreement regarding a public offering of securities.

Key Financial Metrics and Transaction Details

The filing discloses a capital raise transaction rather than operational financial results. Key metrics related to the offering include:

  • Securities Issued: 6,666,667 shares of Common Stock and accompanying Warrants to purchase up to 6,666,667 shares.
  • Offering Price: $1.50 per share (combined price for one share and one warrant).
  • Gross Proceeds: Approximately $10.0 million.
  • Net Proceeds: Approximately $9.1 million (after underwriting discounts and offering expenses).
  • Warrant Terms: Exercise price of $2.00 per share; expiration five years from issuance.
  • Underwriters: Cantor Fitzgerald & Co. and SunTrust Robinson Humphrey, Inc.

The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company's operations.

Material Changes

The primary material change is the execution of an underwriting agreement on May 22, 2019, to raise capital. The offering is expected to close on May 24, 2019, subject to customary closing conditions. This transaction represents a significant increase in the company's cash position upon closing.

Guidance, Outlook, and Risks

Management Commentary: The company intends to use the net proceeds for general corporate purposes. The Warrants are immediately separable and tradeable, though no established trading market exists, and the company does not intend to list them on a national exchange.

Risks and Contingencies:

  • Warrant Exercise Limitations: Holders are prohibited from exercising warrants if it results in beneficial ownership exceeding 4.99% of outstanding shares (adjustable to 9.99% with 61 days' notice).
  • Fundamental Transactions: In the event of a merger, acquisition, or sale of substantially all assets, warrant holders may receive cash equal to the warrant's value (calculated via Black-Scholes model) or adjusted securities.
  • Liquidity of Warrants: There is a risk that a trading market for the Warrants may not develop.

Investor Verification Checklist

  • Confirm the closing date of the offering (expected May 24, 2019) and the actual net proceeds received.
  • Review the full Underwriting Agreement (Exhibit 1.1) and Form of Warrant (Exhibit 4.1) for specific covenants and adjustment mechanisms.
  • Monitor the company's use of the approximately $9.1 million in net proceeds.
  • Verify if a secondary market develops for the Warrants, given the company's statement that no listing is planned.
  • Check subsequent filings for any dilution effects from warrant exercises or future capital raises.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.